VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.57 USD
-0.03 (-4.24%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.57 0.00 (-0.70%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
VBIV 0.57 -0.03(-4.24%)
Will VBIV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VBIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VBIV
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
VBIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for VBIV
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
VBI Vaccines FY Non-GAAP EPS of $3.96
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Soars with Hepatitis B Vaccine Success
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules